Dr. Phung is a clinical associate professor of pediatrics at Oklahoma State University Center for Health Sciences in Tulsa, Oklahoma. He is currently a pediatric acute care hospitalist at Saint Francis Children's Hospital. Dr. Phung received his Bachelor of Science in Physiology and General Business Administration at Oklahoma State University and his Doctorate at Oklahoma State University Center for Health Sciences. He is board certified in pediatrics. Dual Fellow of American Academy of Pediatrics (FAAP) and American College of Osteopathic Pediatricians (FACOP). Dr. Phung completed Masters of Health Care & Business Administration from Oklahoma State University School of Health Care Administration. Dr. Phung also earned the Master of Public Health in Applied Analytic Methods & Epidemiology and Health Informatics from Yale University.

Dr. Phung is a primary and/or co-investigator in the following: 

Cowboys Get Healthy, Get Fit: A medical-community collaborative program for healthy lifestyle changes in overweight & obese children
Primary Investigator. This retrospective study assessed the effects of the "Cowboys Get Healthy, Get Fit" program, a medical-community collaborative program that works to promote healthy lifestyle changes in overweight and obese children ages 10-16. This study, the first of its kind in Oklahoma, was conducted in collaboration with the local YMCA and Oklahoma's premier Stage 3 & 4 comprehensive obesity treatment center, the Family Health and Nutrition Clinic. The outcome analysis of BMI, aerobic fitness, and lifestyle behaviors results from this study was used to improve the program and support the medical-community model.

Pediatric Palliative Care (PPC)
Primary Investigator. Quality improvement (QI) project with the Department of Pediatric Hematology/Oncology at St. Francis Children’s Hospital & St. Jude’s Affiliate Hospital to develop a pediatric palliative curriculum for pediatric residents in Tulsa, Oklahoma. The curriculum was based on the extrapolated survey results completed by osteopathic and allopathic resident physicians, with 16 comprehensive domains measuring physician self-confidence, clinical skills, and concerns about pediatric end-of-life care. Didactic modules included topics such as nausea/vomiting, dyspnea, delirium, artificial hydration, constipation, depression, and pain management. Clinical modules also included discussions on DNR, hospice, psychosocial issues, breaking bad news, and cultural awareness. Residents were surveyed at least quarterly to measure progress and document changes in confidence. The curriculum lasted for 18 months, designed to be repeated at least twice during the 3-year pediatric residency.

Resilience Study: Threshold and impact of resilience among pediatric cancer families
Co-Investigator & Research Mentor. This pilot study will analyze how family functioning, including parental adjustment and distress, can change during the course of pediatric cancer treatment in order to identify psychological distress and/or those individuals in need of additional support to provide effective interventions for the pediatric cancer patients and their families. The ongoing Resilience Study will focus on the threshold and impact of resilience among pediatric cancer families.

Sub-Investigator: Duties as a “sub-investigator” include: enrolling pediatric patients in the studies, participating in training modules, helping to review research protocols, and analyzing data with the OSU Center for Health Sciences Pediatric Research Department.

Astella APPLES (2016). Prospective, pediatric longitudinal evaluation, to assess the long-term safety of Tacrolimus ointment for the treatment of atopic dermatitis.

Regeneron Protocol R222-RSV-1332 (2016). Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a human monoclonal antibody, REGN2222, for the prevention of medically attended RSV infection in preterm infants.

Merck Protocol v114_004 (2015). Phase I-II, randomized, double-blind, study to evaluate the safety, tolerability, and immunogenicity of V114 in healthy adults and infants.

Norvartis Protocol v58_31 (2014). Phase III, observer-blind, randomized, controlled, multicenter study to evaluate the safety of a trivalent subunit influenza vaccine produced either in mammalian cell culture or in embryonated chicken eggs (Fluvirin^®), in healthy children and adolescents 4 to 17 years of age.

Sanofi Protocol MTA55 (2013). An immunogenicity and safety evaluation of Menactra (Meningococcal [Groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine) when administered to healthy subjects at 9 months and concomitantly with Pentacel vaccine at 15 to 18 months of age.

GSK Protocol HIB-097 (112957) (2013). Partially double-blind clinical study to evaluate consistency and immunogenicity of 3 lots of GSK Biologicals’ HiB vaccine 208108 versus ActHiB and Pentacel at 2, 4, 6, and 15-18 months of age in healthy infants.

Sanofi Hexavalent Study (2012). Phase III, randomized, partially double-blind, active-comparator-controlled, lot-to-lot consistency clinical study to evaluate the safety, tolerability, and immunogenicity of V419 in healthy infants when given at 2, 4, and 6 months of age concomitantly with PREVNAR-13 and RotaTeq.

Novartis Protocol V59_P23 (2012). Phase IIIa, open-label, randomized parallel-group, multi-center study to evaluate the safety of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants.

Novartis Protocol V59_P33 (2012). Phase III, randomized, open-label, controlled multi-center study to evaluate the safety and immunogenicity of 4 doses of MenACWY conjugate vaccine, administered concomitantly with routine vaccines, among infants aged 2 months.

Novartis Protocol V59_36 (2012). Phase III, open-label, multi-center study to evaluate the safety and immunogenicity of 2 or 3 doses of MenACWY conjugate vaccine in healthy infants and the effects of a booster dose of MenACWY administered in the second year of life.

GSK Protocol MMR-157 PRI (2012). Phase II, randomized, observer blind, controlled, multi-center study to assess immunogenicity and antibody persistence following vaccination with GSK’s candidate combined measles, mumps, and rubella vaccine (MMR) versus MMR II according to a one-dose schedule, both administered subcutaneously at 12-15 months of age, concomitantly with Hepatitis A vaccine (HAV), varicella vaccine (VV), and pneumococcal conjugate vaccine (PCV) but at separate sites.

Pfizer Protocol B1971015 (2012). Phase II, randomized, single-blind trial, to assess the safety, tolerability, and immunogenicity of MCV4, TDAP vaccine, and rLP2086 vaccine when administered concomitantly in healthy subjects aged ≥10 to <13 years.

Pfizer Protocol B1971011 (2012). Phase II, randomized, active controlled, observer-blinded, to assess the safety, tolerability, and immunogenicity of GARDASIL (HPV) vaccine and rLP2086 vaccine when administered concomitantly in healthy subjects aged ≥11 to <18 years.

Publications in a print format

Phung B, et al. (2023, July). OSU and OMECO Department of Pediatrics “Resident Pocket Manual” 12^th edition

Phung B, et al. (2021, June). OSU and OMECO Department of Pediatrics “Resident Pocket Manual” 10^th edition

Phung B, et al. (2020, June). OSU and OMECO Department of Pediatrics “Resident Pocket Manual” 9^th edition

Phung B, et al. (2019, July). OSU and OMECO Department of Pediatrics “Resident Pocket Manual” 8^th edition

Phung B, et al. (2018, July). OSU and OMECO Department of Pediatrics “Resident Pocket Manual” 7^th edition

Phung B, et al. (2017, July). OSU and OMECO Department of Pediatrics “Resident Pocket Manual” 6^th edition

Phung B, et al. (2016, July). OSU and OMECO Department of Pediatrics “Resident Pocket Manual” 5^th edition

Phung B, et al. (2015, 2014, July). OSU and OMECO Department of Pediatrics “Resident Pocket Manual” 4^th edition

Phung B. (2013, September) Baby Owner’s Manual, 2^nd Edition

Phung B. (2013, July) Manual for Pediatric Residency Research, Abstracts, Posters, and QI Projects 1^st edition

Phung B, et al. (2013, July). OSU and OMECO Department of Pediatrics “Resident Pocket Manual” 3^rd Edition

Phung B, et al. (2012, July). OSU and OMECO Department of Pediatrics “Resident Pocket Manual” 2^nd Edition

Phung B, et al. (2011, June). OSU Department of Pediatrics “Resident Pocket Manual” 1^st Edition

Phung B. (2008, February). Various manuals and booklets for “Mini Medical Schools for Kids”

Phung B. (2010-2015). Pediatric Clerkship Study Guide and Prep Review materials for 3^rd year medical students taking the Pediatric COMAT exam.